Association of Omeprazole-Related Myopathy With Drug-Drug and Drug-Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case-Control Study.

ABSTRACT:

Background

Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.

Aims

This study leveraged electronic health record (EHR) and biobank data to validate an interaction between omeprazole and fluconazole and to explore drug-gene interactions (DGIs) between omeprazole and polymorphisms in CYP enzymes.

Materials and methods

A nested case-control design with incidence-density matching was used. Cases were defined as patients who developed myopathy during ongoing

SUBMITTER: Jeong E 

PROVIDER: S-EPMC12530008 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature